Cross sectional study of depression, anxiety and quality of life in glaucoma patients at a tertiary centre in North Kerala

Bindu S Ajith, Nimitha Najeeb, Arino John, Anima VN

Purpose: To determine the magnitude and direction of association of anxiety and depression and the quality of life (QoL) in persons with glaucoma. Methods: This prospective cross-sectional study in conducted in a tertiary eye center in North Kerala included glaucoma patients and normal subjects aged 40–80 years. The Patient Health Questionnaire-9 (PHQ-9), the Generalized Anxiety Disorder-7 (GAD-7), Glaucoma Quality of Life (GQOL), and glaucoma evaluation were performed for all participants. One-way analysis of variance was used for statistical analysis. Results: The study included 148 subjects with glaucoma and 150 subjects without glaucoma. The prevalence of depression (35.81%) and anxiety (25.0%) was significantly higher in glaucoma patients. In a multivariate regression model, PHQ-9 (adjusted OR: 2.39, 95% CI: 1.31–4.38, P < 0.001), GAD-7 (adjusted OR: 2.06, 95% CI: 1.01–4.19, P = 0.01) and GQOL (coefficient: 6.92, 95% CI: 4.52–9.31, P < 0.001) was significantly associated with glaucoma. The GAD-7 score was significantly higher (P = 0.02) in PACG compared to POAG in moderate and severe anxiety, ADL scores (one-way ANOVA, P = 0.001) and GQOL scores (one-way ANOVA, P < 0.001) were significantly associated with vision impairment and blindness. Conclusion: Depression and anxiety are common in glaucoma patients, indicating the need for screening protocols using PHQ and GAD scales to identify persons at risk. The lack of ophthalmic risk factors associated with depression and anxiety emphasizes the importance of psychological evaluation and combined management with a psychiatrist in glaucoma management.

Key words: GAD questionnaire, glaucoma and anxiety, glaucoma and depression, mental health in glaucoma, PHQ questionnaire, quality of life in glaucoma

Methods

The study protocol was approved by the institutional ethics committee and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all participants before enrolment in the study. Consecutive study subjects were recruited from the ophthalmology outpatient and glaucoma unit of the study institute after fulfilling the criteria for inclusion. We included subjects with POAG/PACG in the age group of 40–80 years, with confirmed diagnosis of glaucoma, on regular follow-up, and compliant to prescribed medication. Subjects with secondary glaucoma, with decreased vision attributable to causes other than glaucoma, including age-related cataracts with best-corrected visual acuity <6/60 in the affected eye, lost to follow-up or not compliant with medications, with high refractive errors, those who did not complete the entire questionnaire, and those who did not provide informed consent for the study were excluded. Consecutive subjects with normal visual acuity and without any ocular comorbidity were selected as a comparison group for the study.

Population-based studies from South India have reported a prevalence of 1.62%–3.51% for primary open-angle glaucoma (POAG) and 0.5%–4.3% for primary angle-closure glaucoma (PACG). There are an estimated 6.48 million with POAG and 2.54 million people with PACG in India. An estimated 4.5 million people worldwide have moderate to severe vision impairment, and 3.2 million people have blindness attributable to glaucoma.

Glaucma is a leading cause of blindness (5.81%), and approximately 1.5 million people in India have blindness attributable to glaucoma.

An estimated 10.9%–24.7% of persons with glaucoma may have depression and nearly 13%–30% may have anxiety. The effects of glaucoma on quality of life are reported from several studies from India, but these studies have not explored specifically the possible associations with depression and anxiety. We designed a cross-sectional study to understand the magnitude of depression and anxiety by using previously validated specific instruments in persons with glaucoma in a population of persons seeking care at a tertiary care eye hospital in north Kerala.

© 2022 Indian Journal of Ophthalmology | Published by Wolters Kluwer - Medknow
Each subject enrolled in the study had a comprehensive ophthalmic examination that included uncorrected and best-corrected visual acuity assessments, slit-lamp biomicroscopy assessment of the anterior chamber, gonioscopy assessments of the angle of the anterior chamber, intraocular pressure assessments using a Goldman applanation tonometer, and posterior segment assessments. Subjects with glaucoma had a visual field assessment using an automated Humphrey perimeter and were further classified as mild, moderate, and severe based on the Hodapp–Parrish criteria.\textsuperscript{[14]}

We used three study instruments that had been translated in the regional language and validated previously for use in this population. The questionnaires included the Patient Health Questionnaire-9 (PHQ-9), the Generalized Anxiety Disorder-7 (GAD-7), The Glaucoma Quality of Life (GQOL), and a general questionnaire that collected information on activities of daily living. The PHQ-9 questionnaire has nine questions to assess depression and is a depression module that scores each of nine DSM-IV criteria as 0 (not at all) to 3 (nearly every day). The severity of depression is graded as 0–4 (none), 5–9 (mild), 10–14 (moderate), 15–19 (moderately severe), and 20–27 (severe).\textsuperscript{[15]} Previous studies have reported a sensitivity of 88% and a specificity of 88% for major depression based on a PHQ-9 score of $\geq 10$.\textsuperscript{[15]} The GAD-7 questionnaire that was used to screen for anxiety includes seven questions and was calculated scores from 0 to 3 for every response given by the patient.\textsuperscript{[14]} Scores of 5, 10, and 15 are taken as cut-off points for mild, moderate, and severe anxiety, respectively. The GQOL is a glaucoma-specific questionnaire that is brief, concise, and easy to administer with good validity and reliability.\textsuperscript{[17]} The GQOL module has 15 vision-related items and the item-level responses for each factor are coded on a five-point scale ($1$ = no difficulty and $5$ = severe difficulty). Participants who do not perform the activity due to non-visual causes are marked as 0. The GQOL items are grouped into four subscales: 1) Central and near vision (two items); 2) Peripheral vision (six items); 3) Dark adaptation and glare (six items); and 4) Outdoor mobility (one item). The total score is derived by summing all item-level response scores. Higher GQOL-15 scores suggest lower QOL. Subscale scores are derived by coding the item-level responses on a numerical interval scale ranging from 0 (no difficulty) to 100 (severe difficulty). GQOL-15 correlates strongly with visual field loss and other psychophysical measures of visual function.

The questionnaires were self-completed by the participants. A counselor guided individuals who needed help in filing the questionnaire without prompting any answers. The questionnaires were administered in the regional language (Malayalam).

The sample size for the study was estimated as 151 cases and 151 controls based on an 80% power, two-sided confidence level of 95, an anticipated prevalence of depression of 10% in the controls, and the ability to detect a least minimum odds ratio of 2.5 and a case-control ratio of 1:1 for an unmatched case-control allocation.

The study data were entered into an anonymized MS Excel spreadsheet and then exported to SPSS V 20.0 for further analysis. Continuous variables were expressed as mean $\pm$ SD and categorical variables were expressed as proportions. A Fishers exact test was used to compare categorical variables and the students $t$-test and the one-way analysis of variance test (one-way ANOVA) were used to compare continuous variables. A multivariate regression model that included factors found significant in a bivariate model was used to further explore the association of PHQ-9, GAD-7, and GQOL with glaucoma. Associations were expressed as adjusted odds ratio (OR) and regression coefficient and the 95% confidence intervals (95% CI) around the point estimates. $P < 0.05$ was considered statistically significant.

Results

The study included 148 subjects with glaucoma (66 subjects with PACG and 82 subjects with POAG) and 150 subjects without ocular morbidity. The mean $\pm$ SD age of normal subjects (57.00 $\pm$ 10.15) was lower than that of subjects with glaucoma (62.47 $\pm$ 9.29) in the study ($P < 0.001$). The baseline characteristics of the study population are presented in Table 1.

All the subjects included in the normal group had normal visual acuity. One hundred (67.57%) subjects with glaucoma had a visual acuity better than 6/18 in the better eye, 41 (27.70%) had a visual acuity between 6/18 and 6/60 in the better eye, and 7 (4.73%) subjects had a visual acuity worse than 6/60 in the better eye. Fifty-six (37.84%) of subjects with glaucoma had mild visual field defects in the better eye, 68 (45.95%) subjects had moderate visual field defects in the better eye, and 24 (16.22%) had severe visual field defects in the better eye. The visual acuity did not differ significantly between POAG and PACG ($P = 0.99$). Mild visual field defects were significantly more common in the PACG group (50.0% vs. 28.05%) compared to POAG while severe visual field defects were more common in the POAG group (18.64% vs. 13.64%) compared to PACG ($P = 0.03$).

Table 2 presents the self-reported limitations of respondents to health-related events. Difficulty in driving, watching TV or reading, and hearing disturbances were significantly higher in persons with glaucoma compared to the normal study population. The overall prevalence of depression and anxiety in the study population was 26.17% (n = 78) and 18.46% (n = 55), respectively. The prevalence of depression (35.81%, $P < 0.001$) and anxiety (25.00%, $P = 0.004$) was significantly higher in persons with glaucoma compared to the normal study population.

Table 3 presents the distribution of PHQ9, GAD7, ADL, and GQOL scores by subjects with glaucoma and normal subjects. PHQ-9 scores, GAD-7 scores, and GQOL scores were significantly higher in persons with glaucoma, although ADL scores were nearly similar between the two groups. Severe depression and anxiety were found in 6.76% and 4.05% of persons with glaucoma in the study population, respectively.

We used a multivariate regression model to further explore the association of PHQ-9, GAD-7, and GQOL with glaucoma. After adjusting for age, sex, education, widowed, currently working, earning status, and diabetes mellitus in a multivariate logistic regression model, PHQ-9 (adjusted odds ratio: 2.39, 95% CI: 1.31–4.38, $P < 0.001$) and GAD-7 (adjusted odds ratio: 2.06, 95% CI: 1.01–4.19, $P = 0.01$) remained significantly associated with glaucoma. GQOL (coefficient: 6.92, 95% CI: 4.52–9.31, $P = 0.001$) was significantly associated with glaucoma in a multivariate linear regression model.
Table 1: Comparison of clinic-demographic characteristics between persons with glaucoma and the normal controls in the study

|                        | Normal (n=150) | Glaucoma (n=148) | P     |
|------------------------|---------------|------------------|-------|
| Mean Age±SD            | 57.00±10.15   | 62.47±9.29       | <0.001|
| Males                  | 75 (50.00%)   | 81 (54.73%)      | Fishers exact P=0.41|
| Females                | 75 (50.00%)   | 67 (45.27%)      |       |
| Primary School         | 34 (22.67%)   | 51 (34.46%)      | Fishers exact P<0.001|
| High School            | 84 (56.00%)   | 65 (43.92%)      |       |
| Pre-degree             | 0 (0.00%)     | 18 (12.16%)      |       |
| Degree/PG              | 32 (21.33%)   | 14 (9.46%)       |       |
| Currently working      | 69 (46.00%)   | 24 (16.22%)      | Fishers exact P<0.001|
| Currently Married       | 126 (85.14%)  | 122 (82.43%)     | Fishers exact P=0.53|
| Widowed                | 7 (4.73%)     | 18 (12.16%)      | Fishers exact P=0.02|
| Sufficient monthly earning | 116 (77.33%)  | 69 (46.62%)      | Fishers exact P<0.001|
| Self-reported poor health status | 4 (2.67%) | 10 (6.67%)      | Fishers exact P=0.09|
| Hypertension           | 36 (24.00%)   | 50 (33.78%)      | Fishers exact P=0.07|
| Diabetes Mellitus      | 29 (19.33%)   | 56 (37.84%)      | Fishers exact P=0.001|
| Heart Attack           | 10 (6.67%)    | 13 (8.78%)       | Fishers exact P=0.52|
| Heart diseases         | 2 (1.33%)     | 7 (4.73%)        | Fishers exact P=0.10|
| Thyroid disorders      | 15 (10.00%)   | 11 (7.43%)       | Fishers exact P=0.54|
| High Cholesterol      | 5 (3.33%)     | 22 (14.86%)      | Fishers exact P<0.001|
| Stroke                 | 7 (4.67%)     | 0 (0.00%)        | Fishers exact P=0.01|
| Cancer                 | 9 (6.00%)     | 4 (2.70%)        | Fishers exact P=0.26|
| Arthritis              | 0 (0.00%)     | 9 (6.08%)        | Fishers exact P=0.0002|
| Asthma                 | 1 (0.67%)     | 12 (8.11%)       | Fishers exact P=0.001|

Table 2: Comparison of self-reported health-related problems between the normal controls and persons with glaucoma in the study

|                  | Normal       | Glaucoma     | P     |
|------------------|--------------|--------------|-------|
| Difficulty in driving | 22 (15.49%) | 80 (54.05%)  | Fishers exact P<0.001|
| Difficulty watching TV/Reading | 4 (2.84%) | 35 (23.65%)  | Fishers exact P<0.001|
| Experiences hearing loss | 1 (0.67%) | 10 (6.76%)  | Fishers exact P=0.005|
| Uses hearing aids  | 15 (10.00%)  | 45 (30.41%)  | Fishers exact P<0.001|
| Feelings of sadness | 2 (1.33%)  | 22 (14.86%)  | Fishers exact P<0.001|
| Excess weight loss in last 6 months | 13 (8.67%) | 14 (9.46%)  | Fishers exact P=0.84|
| Difficulty in passing urine | 13 (8.67%) | 16 (10.81%)  | Fishers exact P=0.56|
| Difficulty in passing stools | 8 (5.33%) | 18 (12.16%)  | Fishers exact P=0.04|
| Accidental Falls   | 7 (4.67%)    | 14 (9.46%)   | Fishers exact P=0.12|

In Table 4 we compared the PHQ-9, GAD-7, ADL, and GQOL scores by PACG and POAG. PHQ-9, ADL, and GQOL scores did not differ significantly between POAG and PACG, but moderate and severe anxiety on the GAD-7 score was significantly higher (P = 0.02) in PACG compared to POAG. PHQ-9 scores (P = 0.69) and GAD-7 scores (P = 0.42) were not associated with visual acuity; however, ADL scores (one-way ANOVA, P = 0.001) and GQOL scores (one-way ANOVA, P < 0.001) were significantly associated with vision impairment and blindness. PHQ-9 scores (P = 0.26), GAD-7 scores (P = 0.64), ADL scores (one-way ANOVA, P = 0.60) and GQOL scores (one-way ANOVA, P = 0.11) were not associated with severity of visual field loss in the better eye.

Depression was not significantly associated with age (P = 0.13), sex (P = 0.45), education (P = 0.06), current working status (P = 0.07), widowed (P = 0.24), visual acuity (P = 0.59), visual field loss (P = 0.90), and type of glaucoma (P = 0.25) in persons with glaucoma in the study population but was significantly associated with insufficient monthly earnings to meet expenses (P = 0.005). Anxiety was not significantly associated with age (P = 0.38), sex (P = 0.26), current working status (P = 0.71), visual acuity (P = 0.64), visual field loss (P = 0.53), and type of glaucoma (P = 0.57) in persons with glaucoma in the study population but was significantly associated with lower education levels (P = 0.02), current working status (P = 0.004) status, and insufficient monthly earnings to meet expenses (P = 0.001). The severity of depression (P = 0.49) and anxiety (P = 0.57) were not associated with the number of glaucoma medications or the use of timolol or similar betablockers (P = 0.62 for depression and P = 0.34 for anxiety).
Discussion

Glaucoma is a silent progressive disease with visual acuity and field loss that can affect the quality of vision, social life, and psychosocial behavior of the individual. More than one-third (35.81%) and one-fourth (25.0%) of persons with glaucoma in our study had depression and anxiety, respectively. The quality of life was significantly lower ($P < 0.001$) in persons with glaucoma compared to persons without glaucoma; however, the activities of daily life did not differ significantly between persons with glaucoma and normal persons. We did not find a significant difference in depression, quality of life, and activities of daily living by the type of glaucoma, but moderate to severe anxiety was significantly higher in persons with PACG.

We found several demographic factors that can influence depression and anxiety, such as current working status, economic status, and separation/widowhood, to be significantly more in persons with glaucoma compared to the normal population. Just over half (54.73%) of the persons with glaucoma in our study were males, and we did not find a significant gender difference among persons with glaucoma in this study. A previous study from south India by Kumar et al. had reported that 63% of their study population were males. However, several other studies have reported that the distribution of glaucoma is more in females. The lack of a gender difference in our study population may be reflective of the equal access to healthcare facilities in Kerala as this was a hospital-based study and not a population-based study. Persons with glaucoma were older than normal in our study and reflects the increasing prevalence of the disease with age. Most of the study population were educated and hence able to self-administer the screening instruments. Persons with glaucoma were less likely to be currently working compared to the normal population and hence more likely to be worried about sufficient monthly income to meet expenses. The proportion of widowed or separated persons was 12.6% among persons with glaucoma and is similar to the 8% reported in a previous study by Kalyani et al.

We found a prevalence of 20.9% for mild depression, 8.1% for moderate, and 6.7% for severe depression in our study, which is similar to a previous study by Agorastos et al. that reported a prevalence of 24.4% for mild, 9.3% for moderate, and 2.3% for severe depression among glaucoma patients. The overall prevalence of depression (35.81%) in persons with glaucoma was not significantly different from a study by Lim.

### Table 3: Comparison of the PHQ9, GAD-7, ADL scores, and glaucoma quality of life scores between persons with glaucoma and normal controls in the study

|                      | Normal          | Glaucoma        | $P$     |
|----------------------|-----------------|-----------------|---------|
| **Patient Health Questionnaire-9** |                 |                 |         |
| No depression        | 125 (83.33%)    | 95 (64.19%)     | One-way |
| Mild depression      | 20 (13.33%)     | 31 (20.95%)     | ANOVA   |
| Moderate depression  | 5 (3.33%)       | 12 (8.11%)      | $P<0.001$ |
| Severe depression    | 0 (0.00%)       | 10 (6.76%)      |         |
| **Generalized Anxiety Disorder-7** |             |                 |         |
| No anxiety           | 132 (88.00%)    | 111 (75.00%)    | One-way |
| Mild anxiety         | 14 (9.33%)      | 24 (16.22%)     | ANOVA   |
| Moderate anxiety     | 4 (2.67%)       | 7 (4.73%)       | $P=0.007$ |
| Severe anxiety       | 0 (0.00%)       | 6 (4.05%)       |         |
| **Activity of Daily Living score (Mean±SD)** | 14.45±2.33 | 14.21±3.26 | $t$‑test $P=0.45$ |
| **Glaucoma Quality of Life score (Mean±SD)** | 18.86±4.46 | 27.5±12.82 | $t$‑test $P<0.001$ |

### Table 4: Comparison of the PHQ9, GAD-7, ADL scores, and glaucoma quality of life scores between persons with POAG and PACG in the study

|                      | Primary Angle Closure Glaucoma ($n=66$) | Primary Open Angle Glaucoma ($n=82$) | $P$     |
|----------------------|----------------------------------------|--------------------------------------|---------|
| **Patient Health Questionnaire-9** |                          |                                      |         |
| No depression        | 39 (59.09%)                            | 56 (68.29%)                          | One way |
| Mild depression      | 16 (24.24%)                            | 15 (18.29%)                          | ANOVA   |
| Moderate depression  | 4 (6.06%)                              | 8 (9.76%)                            | $P=0.24$ |
| Severe depression    | 7 (10.61%)                             | 3 (3.66%)                            |         |
| **Generalized Anxiety Disorder-7** |                          |                                      |         |
| No anxiety           | 48 (72.73%)                            | 63 (76.83%)                          | One-way |
| Mild anxiety         | 8 (12.12%)                             | 16 (19.51%)                          | ANOVA   |
| Moderate anxiety     | 4 (6.06%)                              | 3 (3.66%)                            | $P=0.02$ |
| Severe anxiety       | 6 (9.09%)                              | 0 (0.00%)                            |         |
| **Activity of Daily Living score (Mean±SD)** | 14.50±3.84 | 13.98±2.07 | $t$‑test $P=0.33$ |
| **Glaucoma Quality of Life score (Mean±SD)** | 28.17±13.88 | 26.96±11.95 | $t$‑test $P=0.57$ |
N C et al.\textsuperscript{[19]} from Singapore that reported a prevalence of 30% in persons with glaucoma. Insufficient monthly earning was significantly associated with depression and anxiety in this study, and lower educational levels and widowed or separated status were additionally associated with anxiety. These associations with anxiety and depression are possibly related to the social support network and worries about long-term healthcare expenditure.

Depression and anxiety were not associated with the visual acuity or visual fields in the better or worse eye in this study. The lack of association with actual visual acuity and fields suggests the possibility that depression and anxiety are related to the anticipation or perception of deteriorating vision and field loss rather than the actual visual acuity or field status. Previous studies have reported similar results, including in patients with one eye blindness from glaucoma.\textsuperscript{[20–22]} Holló G et al. reported a higher risk of anxiety, depression, hopelessness about the future, and decreased self-assessments of general health in glaucoma patients with good visual acuity and visual functions of the fellow eye with no risk of future visual impairment.\textsuperscript{[21]} Rulli et al.\textsuperscript{[23]} reported that psychological alterations in persons with glaucoma can occur with an actual decline in the visual functions and may also occur by the possibility of future functional decline or glaucomatous progression.

There was no significant difference in the prevalence of depression between POAG and PACG but the levels of depression were significantly higher in PACG patients (40.9%) than in POAG patients (31.70%) in our study. There was a significant difference in the anxiety levels of PACG (27.2%) compared to POAG (16%), $P = 0.02$, which is consistent with results from a previous study from China.\textsuperscript{[23]}

There are conflicting reports in the literature on the association of topical β-blockers and depression. Bali et al.\textsuperscript{[24]} reported that patients on topical β-blockers were 4.9 times more likely to have depression as compared with normal controls, whereas other studies\textsuperscript{[25,26]} did not find any increased risk of depression. We did not find any significant association between the use of topical β blockers/prostaglandin analogs and depression or anxiety in our study. We also did not see any significant association for depression or anxiety with the mean number of glaucoma medications used in persons with glaucoma in the study. The fear of loss of vision and visual fields, loss of functional activity, and possible side effects of treatment can lead to depression. We found that persons with glaucoma reported greater difficulty in routine daily activities and sadness compared to the normal study population, which is consistent with the results from previous studies worldwide.

Redundant retinal oxidative stress, which leads to the extensive loss of intrinsically photosensitive retinal ganglion cells (ipRGCs), is one of the pathophysiological mechanisms of glaucomatous optic nerve damage.\textsuperscript{[27]} These ipRGCs have a major role in nonvisual phototransduction through the retinohypothalamic tract to the suprachiasmatic nucleus (SCN) and in the regulation of the pineal gland and melatonin.\textsuperscript{[28,29]} Thus, glaucoma affects the photo-dependent circadian rhythm alterations and melatonin production. Studies on circadian rhythm misalignment have shown a close relation between sleep disorders and depression.\textsuperscript{[30]} This misalignment of chronoreceptors is relatively associated with retinal ganglion cell death.\textsuperscript{[31]} While neuropsychiatric studies by Agorastos et al.\textsuperscript{[32]} suggested a relation of visual field defect and depression and anxiety in glaucoma patients, the results of our study suggest that visual impairment is not a sole factor for the development of mental health problems in persons with glaucoma. We hypothesize that depression and glaucoma are related directly irrespective of visual acuity or field defects and can relate to the theory of chronodisruption. However, we need to study this possible relation further with larger samples and diverse populations.

The overall prevalence of anxiety (18.46%) in our study population is comparable to the prevalence of generalized anxiety disorder in India as reported by Reddy and Chandrashekar et al.,\textsuperscript{[33]} which found anxiety in 20.7% (18.7%–22.7%) of the general population of India. We found a prevalence of 25% anxiety in persons with glaucoma, including mild anxiety (16.22%), moderate (4.73%), and severe anxiety (4.05%).

Glaucoma influences the quality of life similar to other chronic systemic diseases such as diabetes and dementia.\textsuperscript{[33]} The Glaucoma quality of life (GQOL) scores were significantly higher compared to the normal population, indicative of a reduced quality of life in persons with glaucoma. Reduced QoL in glaucoma patients has been reported earlier in a cross-sectional study by Sherwood et al.,\textsuperscript{[34]} and we found similar results. The reduction in QoL was significant after adjusting for clinic-demographic factors in a multivariate linear regression model. The reduced QoL may be impacted by the depression, anxiety, and reduction in functional activities associated with glaucoma that may be influenced by the perception or possibility of loss of vision rather than actual loss of vision.

The lack of association with ocular clinical factors such as visual acuity, fields, type of glaucoma, and medications suggests that targeted high-risk-subgroup screening of persons with glaucoma is not feasible. The high prevalence of depression, anxiety, and reduced QoL indicates that it may be necessary to screen all persons with glaucoma for anxiety and depression. The PHQ-9 and GAD questionnaires are easily available, easy to administer, do not take much additional time, and can be self-administered and scored immediately.

To our knowledge, this is the first study in South India to report the prevalence of depression and anxiety among patients with glaucoma using validated scales such as PHQ-9 and GAD-7. The questionnaires were self-administered, minimizing the possibility of prompted responses. All subjects had a detailed ophthalmic examination and diagnosis of glaucoma. However, the cross-sectional study design does not allow us to comment on possible causal relations between glaucoma, depression, and anxiety. The single-center nature of the study and the hospital-based design are limitations that limit the generalization of the results to a larger population due to the possibility of selection bias. The PHQ-9 and GAD-7 are screening instruments and we have not correlated the diagnosis by screening with clinical diagnosis after a psychiatry consultation in this study. The study overlapped with the COVID-19 pandemic and the first lockdown, and we do not know how or if that possibly influenced the estimates of depression and anxiety in this population.
Conclusion

The higher prevalence of depression and anxiety in persons with glaucoma may necessitate the integration of screening protocols using PHQ and GAD scales to identify persons at risk for depression and anxiety. The lack of ophthalmic risk factors associated with depression and anxiety emphasizes the importance of psychological evaluation and combined management with a psychiatrist in glaucoma management. Further studies on the cumulative probability of visual field and visual acuity loss in persons with glaucoma may help in more focused counseling and may reduce anxiety and depression associated with a perceived possibility of vision impairment and blindness.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Jacob A, Thomas R, Koshi SP, Braganza A, Muliyi J. Prevalence of primary glaucoma in an urban south Indian population. Indian J Ophthalmol 1998;46:81-6.
2. Ramakrishnan R, Nirmalan PK, Krishnadad R, Thulasiraj RD, Tielsch JM, Katz J, et al. Glaucoma in a rural population of southern India: The Aravind comprehensive eye survey. Ophthalmology 2003;110:1484-90.
3. Vijaya L, George R, Arvind H, Baskaran M, Paul PG, Ramesh SV, et al. Prevalence of angle-closure disease in a rural Southern Indian population. Arch Ophthalmol 2006;124:403-9.
4. Dandona L, Dandona R, Mandal P, Srinivasis M, John RK, McCarty CA, et al. Angle-closure glaucoma in an urban population in Southern India. The Andhra Pradesh eye disease study. Ophthalmology 2000;107:1710-6.
5. Vijaya L, George R, Baskaran M, Arvind H, Raja P, Ramesh SV, et al. Prevalence of primary open-angle glaucoma in an urban south Indian population and comparison with a rural population. The Chennai Glaucoma Study. Ophthalmology 2008;115:648-54.e1.
6. Dandona L, Dandona R, Srinivasis M, Mandal P, John RK, McCarty CA, et al. Open-angle glaucoma in an urban population in southern India: The Andhra Pradesh eye disease study. Ophthalmology 2000;107:1702-9.
7. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaiete T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990-2020: A systematic review and meta-analysis. Lancet Glob Health 2017;5:e1221-34.
8. Nangia V, Jonas JB, George R, Lingam V, Ellwein L, Cicinelli MV, et al. Prevalence and causes of blindness and vision impairment: Magnitude, temporal trends and projections in South and Central Asia. Br J Ophthalmol 2019;103:871-7.
9. Mousavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: Results from the World Health Surveys. Lancet 2007;370:851-8.
10. Wilson MR, Coleman AL, Yu F, Fong Sasaki I, Bing EG, Kim MH. Depression in patients with glaucoma as measured by self-report surveys. Ophthalmology 2002;109:1018-22.
11. Zhang X, Olson DJ, Le P, Lin FC, Fleishman D, Davis RM. The association between glaucoma, anxiety, and depression in a large population. Am J Ophthalmol 2017;183:37-41.
12. Kumar S, Ichhpujpuni P, Singh R, Thakur S, Sharma M, Nagpal N. The impact of primary open-angle glaucoma: Quality of life in Indian patients. Indian J Ophthalmol 2018;66:416-9.
13. Kalyani VKS, Dayal A, Chelkerkar V, Deshpande M, Chakma A. Assessment of psychosocial impact of primary glaucoma and its effect on quality of life of patients in Western India. Indian J Ophthalmol 2020;68:2435-8.
14. Hodapp E, Parrish RK II, Anderson DR. Clinical Decisions in Glaucoma. St Louis: The CV Mosby Co; 1993, p. 52-61.
15. Koenek E, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief screening severity measure. J Gen Intern Med 2001;16:606-13.
16. Seo JG, Park SP, Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine. J Headache Pain 2015;16:97.
17. Mahdaviazad H, Roustaei N, Masoumpour MB, Razegheinjad MR. Psychometric properties of the Glaucoma Quality of Life-15 questionnaire: Use of explanatory factor analysis. J Curr Ophthalmol 2018;30:211-6.
18. Agorastos A, Skevas C, Matthai M, Otte C, Klemm M, Richard G, et al. Depression, anxiety, and disturbed sleep in glaucoma. J Neuropsychiatry Clin Neurosci 2013;25:205-13.
19. Lim NC, Fan CH, Yong MK, Wong EP, Yip LW. Assessment of depression, anxiety, and quality of life in Singaporean patients with glaucoma. J Glaucoma 2016;25:605-12.
20. Jampel HD, Frick KD, Janz NK, Wren PA, Musch DC, Rimal R, et al. Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol 2007;144:238-44.
21. Hölzl G, Sándor NG, Köthy P, Géczy A. Influence of painless one-eye blindness on depression, anxiety and quality of life in glaucoma patients with a normal fellow eye. BMC Ophthalmol 2021;21:89.
22. Rulli E, Quaranta L, Riva I, Poli D, Hollander L, Galli F, et al. Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study. Sci Rep 2018;8:619. doi: 10.1038/s41598-017-19113-z. Erratum in: Sci Rep 2020;10:3189.
23. Arvind BA, Gururaj G, Loganathan S, Amudhan S, Varghese M, Benefal V, et al. Prevalence and socioeconomic impact of depressive disorders in India: Multisite population-based cross-sectional study. BMJ Open 2019;9:e022750.
24. Bali SJ, Parmar T, Arora V, Ichhpujani P, Sagar R, Dada T. Evaluation of major depressive disorder in patients receiving chronic treatment with topical timolol. Ophthalmologica 2011;226:157-60.
25. Kaierman I, Kaierman N, Elhayany A, Vinker S. Topical beta-blockers are not associated with an increased risk of treatment for depression. Ophthalmology 2006;113:1077-80.
26. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-7.
27. Moreno MC, Campanelli J, Sande P, Sánez DA, Keller Sarmiento MI, Rosenstein RE. Retinal oxidative stress induced by high intraocular pressure. Free Radic Biol Med 2004;37:803-12.
28. Jean-Louis G, Zizi F, Lazzaro DR, Wolintz AH. Circadian rhythm dysfunction in glaucoma: A hypothesis. J Circadian Rhythms 2008;6:1.
29. Panda S, Nayak SK, Campo B, Walker JR, Hogenesch JB, Jegla T. Illumination of the melatonin signalling pathway. Science 2005;307:600-4.
30. Sipilä T, Kananen L, Greco D, Donner J, Silander K, Terwilliger JD, et al. An association analysis of circadian genes in anxiety disorders. Biol Psychiatry 2010;67:1163-70.
31. Agorastos A, Huber CG. The role of melatonin in glaucoma: Implications concerning pathophysiological relevance and therapeutic potential. J Pineal Res 2011;50:1–7.
32. Reddy VM, Chandrashekar CR. Prevalence of mental and behavioural disorders in India: A meta-analysis. Indian J Psychiatry 1998;40:149-57.
33. Jung KI, Park CK. Mental health status and quality of life in undiagnosed glaucoma patients: A nationwide population-based study. Medicine (Baltimore) 2016;95:e3523.
34. Sherwood MB, Garcia-Siekavizza A, Meltzer MI, Hebert A, Burns AF, McGorray S. Glaucoma’s impact on quality of life and its relation to clinical indicators. A pilot study. Ophthalmology 1998;105:561-6.